Centessa Pharmaceuticals PLC
CNTA16.420USD
-0.390-2.32%
交易中 （美东）报价延迟15分钟
2.19B总市值
亏损市盈率 TTM
关于 Centessa Pharmaceuticals PLC 公司
Centessa Pharmaceuticals plc 是一家位于英国的临床阶段制药公司。其先进项目包括血友病项目、用于治疗发作性睡病和其他睡眠-觉醒障碍的食欲素激动剂项目以及专注于其 LockBody 技术平台的免疫肿瘤学项目。其先进候选产品 SerpinPC 是一种用于治疗血友病的、处于研究阶段、可能为同类首创的皮下给药新型活化蛋白 C 抑制剂。其食欲素受体 2 (OX2R) 激动剂项目包括 ORX750，这是一种处于研究阶段的口服选择性 OX2R 激动剂，旨在直接针对 1 型发作性睡病中食欲素神经元丢失的潜在病理生理学，并治疗食欲素水平正常的睡眠-觉醒障碍，如 2 型发作性睡病和特发性嗜睡症。该公司还在探索后续食欲素激动剂，以期在一系列睡眠-觉醒障碍和更广泛的神经系统适应症中寻找潜在的扩展机会。
公司简介
公司代码CNTA
公司名称Centessa Pharmaceuticals PLC
上市日期May 28, 2021
CEODr. Saurabh Saha, M.D., Ph.D.
员工数量77
证券类型Depository Receipt
年结日May 28
公司地址3rd Floor
城市ALTRINCHAM
上市交易所NASDAQ Global Select Consolidated
国家United Kingdom
邮编WA14 2DT
电话447391789784
网址https://www.centessa.com/
公司代码CNTA
上市日期May 28, 2021
CEODr. Saurabh Saha, M.D., Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
60.24K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
45.17K
--
Dr. Stephen J. Kanes, M.D., Ph.D.
Dr. Stephen J. Kanes, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Kristen K. Sheppard, Esq.
Mr. Kristen K. Sheppard, Esq.
Senior Vice President Investor Relations
Senior Vice President Investor Relations
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John Crowley
Mr. John Crowley
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Karen Anderson
Ms. Karen Anderson
Chief People Officer
Chief People Officer
--
--
Ms. Tia Bush
Ms. Tia Bush
Chief Technology and Quality Officer
Chief Technology and Quality Officer
--
--
Dr. Arjun Goyal, M.D.
Dr. Arjun Goyal, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mary Lynne Hedley, Ph.D.
Dr. Mary Lynne Hedley, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
60.24K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
45.17K
--
Dr. Stephen J. Kanes, M.D., Ph.D.
Dr. Stephen J. Kanes, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Kristen K. Sheppard, Esq.
Mr. Kristen K. Sheppard, Esq.
Senior Vice President Investor Relations
Senior Vice President Investor Relations
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John Crowley
Mr. John Crowley
Chief Financial Officer
Chief Financial Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月2日 周三
更新时间: 7月2日 周三
持股股东
股东类型
持股股东
持股股东
占比
Medicxi Ventures (UK) LLP
14.94%
Index Ventures SA
7.46%
General Atlantic LLC
7.25%
Adage Capital Management, L.P.
5.20%
Janus Henderson Investors
4.43%
Other
60.72%
持股股东
持股股东
占比
Medicxi Ventures (UK) LLP
14.94%
Index Ventures SA
7.46%
General Atlantic LLC
7.25%
Adage Capital Management, L.P.
5.20%
Janus Henderson Investors
4.43%
Other
60.72%
股东类型
持股股东
占比
Hedge Fund
23.53%
Venture Capital
23.05%
Investment Advisor
19.40%
Investment Advisor/Hedge Fund
15.34%
Private Equity
10.46%
Research Firm
2.54%
Individual Investor
0.50%
Endowment Fund
0.06%
Other
5.12%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
220
133.64M
100.03%
-11.01M
2025Q1
222
135.75M
101.62%
-10.84M
2024Q4
187
130.97M
99.33%
-6.00M
2024Q3
166
123.88M
97.57%
+8.26M
2024Q2
145
101.97M
89.71%
-3.69M
2024Q1
140
90.07M
89.09%
-8.60M
2023Q4
126
85.94M
86.60%
-9.82M
2023Q3
125
84.37M
86.02%
-11.03M
2023Q2
135
82.21M
85.98%
-8.96M
2023Q1
131
78.75M
82.92%
-8.68M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Medicxi Ventures (UK) LLP
19.96M
14.94%
--
--
Apr 24, 2025
Index Ventures SA
9.96M
7.46%
--
--
Apr 24, 2025
General Atlantic LLC
9.68M
7.25%
--
--
Apr 24, 2025
Adage Capital Management, L.P.
6.95M
5.2%
+1.83M
+35.85%
Mar 31, 2025
Janus Henderson Investors
5.92M
4.43%
+1.01M
+20.63%
Mar 31, 2025
T. Rowe Price Associates, Inc.
5.34M
4%
-22.05K
-0.41%
Mar 31, 2025
First Light Asset Management, LLC
4.87M
3.65%
-931.06K
-16.04%
Mar 31, 2025
Farallon Capital Management, L.L.C.
4.33M
3.24%
+835.61K
+23.88%
Mar 31, 2025
Avoro Capital Advisors LLC
4.05M
3.03%
+4.05M
--
Mar 31, 2025
VV Manager LLC
3.93M
2.95%
--
--
Dec 31, 2024
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.98%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
SPDR S&P International Small Cap ETF
0.09%
iShares Biotechnology ETF
0.07%
T Rowe Price Small-Mid Cap ETF
0.05%
Fidelity Nasdaq Composite Index ETF
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.98%
ProShares Ultra Nasdaq Biotechnology
占比0.14%
Invesco Nasdaq Biotechnology ETF
占比0.14%
SPDR S&P International Small Cap ETF
占比0.09%
iShares Biotechnology ETF
占比0.07%
T Rowe Price Small-Mid Cap ETF
占比0.05%
Fidelity Nasdaq Composite Index ETF
占比0%
First Trust IPOX Europe Equity Opportunities ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
